Computer-Aided Detection (CAD) that uses software designed to
improve how radiologists interpret mammograms may instead make
readings less accurate, according to new research. Use of CAD did
not clearly improve the detection of breast cancer. The research
was conducted by investigators at the University of California
Davis Health System, Sacramento, Calif., and colleagues in the
Breast Cancer Surveillance Consortium, which is sponsored by the
National Cancer Institute (NCI), part of the National Institutes
of Health.
The results of the study show that women who got screening mammograms
at centers using CAD devices were more likely to be told their
mammogram was abnormal and thus undergo a biopsy to rule out breast
cancer. Findings appear in the April 5, 2007 issue of the New
England Journal of Medicine and were funded by NCI, the Agency
for Healthcare Research and Quality, and the American Cancer Society.
CAD software analyzes the mammogram image and marks suspicious
areas for radiologists to review, thus assisting them in determining
which images could lead to in serious tumors. CAD was approved
by the U.S. Food and Drug Administration in 1998 and has been incorporated
into many mammography imaging practices, but its effect on the
accuracy of interpretation has been unclear.
?This study points out the need for the use of other techniques
to find cancer at its earliest stages. NCI is incorporating techniques
for imaging at the molecular level into many of its studies and
is also conducting studies to improve the use of CAD and conventional
mammography,? said John E. Niederhuber, M.D., NCI Director. ?In
the end, technology facilitates screening. Ultimately, treatment
requires radiologists working with the examining physician and
the responsible surgeon to put everything together. We worry about
false positives, but we certainly don?t want to miss any cancers,
either.?
Investigators looked at the use of screening mammography in 222,135
women who had 429,345 mammograms. The period of observation was
from 1998 through 2002 and took place at 43 facilities in Colorado,
New Hampshire, and Washington states. The study included 2,351
women who received a diagnosis of breast cancer within one year
after screening and also received a mammogram that did or did not
use CAD.
?Within three years of FDA approval, 10 percent of the mammography
facilities in the country were using CAD,? said lead researcher
Joshua J. Fenton, M.D., UC Davis Health System. ?There had been
no large-scale community-based review of CAD efficacy despite the
rapid adoption of this technology so we did this study to see if
CAD was proving to be beneficial.?
Seven facilities, representing 16 percent of the study sites,
implemented computer-aided detection during the study period. With
the use of CAD, 32 percent more women were recalled for more tests
and 20 percent more women had a breast biopsy. Use of the software
had no clear impact on the early detection of breast cancer. The
study suggests that, if anything, the software may promote the
detection of the least dangerous breast cancers, such as localized, in
situ breast cancers. The effect of in situ cancers
on breast cancer mortality remains unknown and some evidence suggests
that not all develop into serious cancers.
Every time the CAD software marks a real cancer, a radiologist
has to consider about 2,000 additional false-positive marks, making
it very difficult to distinguish between real cancers and those
that are not cancer. The authors estimate that for every additional
woman diagnosed with breast cancer on the basis of CAD, 156 women
are falsely recalled for more tests and 14 had unnecessary biopsies
to exclude cancer.
?It?s unfortunate that the use of the software has proliferated
so widely before we are certain of its benefits,? said Fenton. ?We
need studies to determine if the benefits of the software outweigh
its harms and costs. There is also the potential for new studies
to improve the performance of CAD software.?
The authors estimate that if all mammography facilities adopt
CAD, the annual cost of mammograms in the United States could increase
18 percent, or an additional $550 million nationwide.
For a Q&A on this finding, please go to http://www.cancer.gov/newscenter/pressreleases/CADmammographyQandA.
For more information about cancer, visit http://www.cancer.gov,
or call NCI's Cancer Information Service at 1-800-4 CANCER.